spacer
home > ict
PUBLICATIONS

International Clinical Trials

 

International Clinical Trials (ICT) is a specialist journal designed to provide global coverage of key topics pertinent to the clinical trials sector.

Published quarterly, and edited by Dr Graham Hughes, the journal offers a platform of communication and information-sharing for executive and strategic decision-makers, seeking out new trends and marketing opportunities, as well as putting a spotlight on the latest innovations coming to market. ICT is specifically designed to be of interest to those actively seeking to source services for improved efficiency in what is an increasingly competitive market.

For further information please contact:

Advertising
Nick Matthews   

Editorial
Rupert Gilbey

 


View the digital version of ICT

ict
 
 
Featured in this issue
TRIAL MANAGEMENT
Drug Safety

Active Ingredients


Doing business in new markets brings greater exposure to safety and regulatory risks. Chitra Lele at Sciformix examines how this is prompting a shift to a more proactive pharmacovigilance model with data analysis, stakeholder input and benefit-risk balance at its core.
TRIAL MANAGEMENT
Site Performance

Going Metric

A shared, consistent set of standards and metrics to assess the performance of clinical research sites is moving closer due to an ongoing multi-stakeholder initiative. Greg Koski and Mary Tobin at ACRES, and Eve Shalley at Essex Management report.
  Introduction
Comment from the Editor

As many articles in this edition highlight, the industry is reshaping in the face of multiple pressures and demands – prompting Graham Hughes to offer his take on the coming reformation.

spacer
Edited by
Dr Graham Hughes
Consultant in
Pharmaceutical
Development

Published quarterly in
February, May,
August and November
Banner of Medpace on Samedan
Banner of Pharmarama.ICT on Samedan
Banner of UBC.ICT on Samedan
 
Industry Events

Annual World Drug Manufacturing Summit

1-3 December 2014, Berlin, Germany

Now in its 13th year, the World Drug Manufacturing Summit provides the key tools to overcome the biggest threats facing pharma manufacturers today.
More info >>

 
News and Press Releases

PCI WELCOMES TIM BROWN TO CLINICAL SERVICES GROUP

Philadelphia, PA – July 7th, 2014 - Packaging Coordinators, Inc. (PCI) has announced the addition of Tim Brown to its Global Clinical Services staff, assuming the role of Director of Project Management for North American operations.  Brown is transitioning from PCI’s Commercial Packaging services team at the Rockford site, where PCI operates nine facilities including PCI’s state-of-the-art North American Clinical Packaging, Storage, and Distribution operations.  Brown joins PCI’s Clinical Services team as they are experiencing significant business growth and expansion, evidenced both in personnel growth as well as capital expansions.  In December PCI broke ground on a brand new 97,000 square foot stand-alone Storage and Distribution facility, expected to open in September of 2014.
More info >>

air transport logo

 

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement